Tarsus Pharmaceuticals (TARS) 10-Q2022 Q1 Quarterly report

Filed: 11 May 22, 5:09pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: abandon, accreted, accretion, administer, agreed, AgreementTM, annum, biomarker, biopharma, bring, carcinogenicity, centrally, convince, Derm, desired, differentiate, difficult, drawn, drew, embryofetal, evolve, exposed, face, failure, February, flawed, floating, forecast, greater, grow, higher, hypothetical, inappropriate, inconclusive, industry, insufficient, interpret, jeopardize, Journal, labeling, lengthy, lifted, loan, lowest, manner, marketplace, maturity, mechanism, mild, modestly, modify, multiplying, multitude, national, negotiation, noncompliance, notwithstanding, organizational, pathognomonic, penalty, perception, placebo, preliminary, prescribed, prime, proceed, produce, prolonged, promote, properly, prospective, protocol, prove, quality, quarantine, raw, reclassification, recommended, redesigned, restructured, risky, root, sample, satisfactory, shortage, shorten, side, Silicon, small, smaller, speed, Street, structure, susceptible, suspend, SVB, technique, teen, twelve, unacceptable, unanticipated, undesirable, unexpected, unpaid, unplanned, unpredictable, Valley, vary, varying, waiver, Wall, withdraw

Removed: absence, adjusted, affecting, annually, Article, assessed, ASU, biotechnology, burden, calculate, card, carefully, category, certificate, charged, clinic, collateral, commercialized, comparison, component, conclude, Concurrent, crucial, daily, decision, depreciated, designee, determination, determining, developed, enacted, enhanced, estimating, FASB, formally, forward, franchise, goodwill, Hedging, impairment, incorporation, instituted, insurance, interaction, intraperiod, issue, Joint, lacked, legally, life, marketability, nonqualified, notice, objective, observational, paralyze, performing, periodic, presenting, professional, program, psychosocial, published, realizable, recognizing, recoverable, recovered, Regulation, represented, restated, retroactive, reverse, ROU, screening, separate, separately, settled, shorter, showed, Simplifying, split, surface, symptomatic, Task, taxable, taxing, temporary, test, Topic, trading, training, undiscounted, unexercised, vii, viii, visit, weighting, worsening

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

TARS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Tarsus Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Leo M. Greenstein, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act

of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and

result of operations of the Company.

Date: May 11, 2022

By:

/s/ Leo M. Greenstein

Leo M. Greenstein

Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)